<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274456</url>
  </required_header>
  <id_info>
    <org_study_id>CA024</org_study_id>
    <nct_id>NCT00274456</nct_id>
  </id_info>
  <brief_title>Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label study conducted comparing the toxicity and antitumor activity of
      ABI-007 (Abraxane®, nab®-paclitaxel) to docetaxel (Taxotere).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized study to compare the following regimens with respect to
      toxicity and antitumor activity:

        -  the maximum tolerated dose (MTD) of ABI-007 300 mg/m^2 every 3 weeks;

        -  ABI-007 100 mg/m^2 administered weekly for 3 weeks with a 1 week rest;

        -  ABI-007 150 mg/m^2 administered weekly for 3 weeks with a 1 week rest;

        -  the standard dose and schedule of Taxotere (100 mg/m^2 every 3 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator</measure>
    <time_frame>Day 1 up to 95 weeks</time_frame>
    <description>Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is &gt;= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response</measure>
    <time_frame>Day 1 up to 95 weeks</time_frame>
    <description>Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Progression-free Survival (PFS)</measure>
    <time_frame>Day 1 up to 95 weeks</time_frame>
    <description>PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression</measure>
    <time_frame>Day 1 - 95 weeks</time_frame>
    <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression</measure>
    <time_frame>Day 1 - 95 weeks</time_frame>
    <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate for Overall Survival (OS)</measure>
    <time_frame>Day 1 to 221 weeks</time_frame>
    <description>Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment-Emergent, Treatment-Related Adverse Events</measure>
    <time_frame>Day 1 up to 125 weeks</time_frame>
    <description>Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts</measure>
    <time_frame>Day 1 up to 125 weeks</time_frame>
    <description>Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.</description>
  </other_outcome>
  <other_outcome>
    <measure>Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts</measure>
    <time_frame>Day 1 up to 125 weeks</time_frame>
    <description>Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ABI-007 300 mg/m^2 q3w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-007 100 mg/m^2 weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-007 150 mg/m^2 weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 100 mg/m^2, q3w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-007</intervention_name>
    <description>ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.</description>
    <arm_group_label>ABI-007 300 mg/m^2 q3w</arm_group_label>
    <arm_group_label>ABI-007 100 mg/m^2 weekly</arm_group_label>
    <arm_group_label>ABI-007 150 mg/m^2 weekly</arm_group_label>
    <other_name>Abraxane®</other_name>
    <other_name>nab®-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel dosed q3w at 100 mg/m^2</description>
    <arm_group_label>Docetaxel 100 mg/m^2, q3w</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients had to meet the following criteria to be eligible for the study:

          1. Pathologically confirmed adenocarcinoma of the breast.

          2. No prior chemotherapy for metastatic breast cancer.

          3. Stage IV disease.

          4. Measurable disease (must have been ≥ 2.0 cm, except for pulmonary lesions that were
             well documented on CT scan that were ≥ 1.0 cm).

          5. At least 3 weeks since prior cytotoxic chemotherapy (patients should have recovered
             from all acute effects of such therapy.

          6. At least 4 weeks since radiotherapy, with full recovery. The measurable disease was
             completely outside the radiation portal or there was radiologic or clinical exam proof
             of progressive disease within the radiation portal.

          7. At least 4 weeks since major surgery, with full recovery.

          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          9. Age ≥18 years.

         10. Patient had the following blood counts at Baseline:

               -  Absolute neutrophil count (ANC) ≥1.5*10^9 cells/L

               -  Platelets ≥100*10^9 cells/L

               -  Hemoglobin (Hgb) ≥9 g/dL.

         11. Patient had the following baseline blood chemistry levels:

               -  Aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT
                  [SGPT])≥2.5x upper limit of normal (ULN) range

               -  Total bilirubin normal

               -  Alkaline phosphatase ≥2.5x ULN (unless bone metastasis is present in the absence
                  of liver metastasis)

               -  Creatinine ≥1.5 mg/dL.

         12. Peripheral neuropathy Grade 0 or 1 by National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Events (CTCAE).

         13. If female of childbearing potential, pregnancy test was negative (within 72 hours of
             the first dose of study drug).

         14. If fertile, the patient agreed to use an effective method to avoid pregnancy for the
             duration of the study.

         15. Informed consent had been obtained.

        Exclusion Criteria:

        Patients who met any of the following criteria were excluded from the study:

          1. Prior neo-adjuvant or adjuvant chemotherapy was allowed. No prior chemotherapy for
             metastatic disease was allowed. If a taxane was part of the adjuvant regimen, at least
             one year should have transpired since completion of taxane regimen.

          2. Cumulative life-time dose of doxorubicin &gt;360 mg/m^2. Doxorubicin was allowed as prior
             neo-adjuvant or adjuvant therapy but not for metastatic disease.

          3. Concurrent immunotherapy or hormonal therapy for breast cancer.

          4. Parenchymal brain metastases, unless documented to be clinically and radiographically
             stable for at least 6 months after treatment.

          5. Serious intercurrent medical or psychiatric illness, including serious active
             infection.

          6. History of class II-IV congestive heart failure.

          7. History of other malignancy within the last 5 years which could affect the diagnosis
             or assessment of breast cancer.

          8. Patients who had received an investigational drug within the previous 3 weeks.

          9. Patient was enrolled in a different clinical study in which investigational procedures
             were performed or investigational therapies were administered. Also, a patient was not
             permitted enroll in such clinical trials while participating in this study.

         10. Pregnant or nursing women

         11. Patients with prior hypersensitivity to either Taxol or Taxotere.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Iglesias, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Sites in Russia and the Ukraine</name>
      <address>
        <city>Kiev</city>
        <zip>01021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <results_reference>
    <citation>Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611-9. doi: 10.1200/JCO.2008.18.5397. Epub 2009 May 26. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739.</citation>
    <PMID>19470941</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <results_first_submitted>February 7, 2011</results_first_submitted>
  <results_first_submitted_qc>May 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer, nab paclitaxel, docetaxel,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three hundred and two patients were enrolled and randomized between November 2005 and June 2006, of which 300 received study drug and were evaluated for response and safety. Data below represents data cut-off 31 March 2008.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABI-007 300 mg/m^2 q3w</title>
          <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
        </group>
        <group group_id="P2">
          <title>ABI-007 100 mg/m^2 Weekly</title>
          <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
        </group>
        <group group_id="P3">
          <title>ABI-007 150 mg/m^2 Weekly</title>
          <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
        </group>
        <group group_id="P4">
          <title>Docetaxel 100 mg/m^2 q3w</title>
          <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>At Least One Response Assessment</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">Treatment completed upon progressive disease</participants>
                <participants group_id="P2" count="49">Treatment completed upon progressive disease</participants>
                <participants group_id="P3" count="39">Treatment completed upon progressive disease</participants>
                <participants group_id="P4" count="29">Treatment completed upon progressive disease</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still on treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unacceptable toxicity</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABI-007 300 mg/m^2 q3w</title>
          <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
        </group>
        <group group_id="B2">
          <title>ABI-007 100 mg/m^2 Weekly</title>
          <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
        </group>
        <group group_id="B3">
          <title>ABI-007 150 mg/m^2</title>
          <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest.</description>
        </group>
        <group group_id="B4">
          <title>Docetaxel 100 mg/m^2 q3w</title>
          <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="74"/>
            <count group_id="B5" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="9.47"/>
                    <measurement group_id="B2" value="55.4" spread="9.59"/>
                    <measurement group_id="B3" value="53.3" spread="9.14"/>
                    <measurement group_id="B4" value="55.4" spread="11.57"/>
                    <measurement group_id="B5" value="53.9" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, Non-Hispanic, Non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White, Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.56" spread="12.668"/>
                    <measurement group_id="B2" value="73.64" spread="14.670"/>
                    <measurement group_id="B3" value="76.24" spread="13.437"/>
                    <measurement group_id="B4" value="75.99" spread="14.034"/>
                    <measurement group_id="B5" value="74.59" spread="13.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>A scale used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (restrictive but ambulatory)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (ambulatory but unable to work)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (limited self-care) + 4 (completely disabled)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pre-menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Assessment of Sensory Neuropathy</title>
          <description>The physician assessed sensory neuropathy using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) of “Neurology -- Neuropathy – Sensory”. The scale is 0=normal and 1=asymptomatic; loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Primary Diagnosis and from First Metastasis/Relapse to Study Entry</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Time from Primary Diagnosis to Study Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.24" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="B2" value="1.17" lower_limit="0.0" upper_limit="14.9"/>
                    <measurement group_id="B3" value="0.97" lower_limit="0.0" upper_limit="16.9"/>
                    <measurement group_id="B4" value="1.27" lower_limit="0.0" upper_limit="14.3"/>
                    <measurement group_id="B5" value="1.23" lower_limit="0.0" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time from First Metastasis/Relapse to Study Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.02" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="B2" value="0.04" lower_limit="0.0" upper_limit="8.1"/>
                    <measurement group_id="B3" value="0.05" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="B4" value="0.04" lower_limit="0.0" upper_limit="2.6"/>
                    <measurement group_id="B5" value="0.04" lower_limit="0.0" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Site of Metastasis/Relapse</title>
          <description>Patients may have multiple sites of metastasis/relapse.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin/Soft Tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraclavicular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Axilla</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung/Thoracic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic/Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen/Peritoneal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dominant Current Site of Metastasis/Relapse</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at Primary Diagnosis</title>
          <description>Invasive breast cancer stages:
Stage I-cancer cells are breaking through to or invading normal surrounding breast tissue.
Stage IIa-breast tumor about 2cm and involvement of ancillary lymph nodes.
Stage IIb-a larger tumor than earlier phases.
Stage IIIa-axillary lymph nodes clumping together.
Stage IIIb-spread further to the skin, breast bone or chest wall.
Stage IIIc-expanded involvement of lymph nodes.
Stage IV-cancer that has spread beyond the breast and nearby lymph nodes to other organs of the body.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IIIc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Lesions (Target + Non-Target)</title>
          <description>Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeat measurements (either by imaging techniques or clinically).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-3 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator</title>
        <description>Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is &gt;= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.</description>
        <time_frame>Day 1 up to 95 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator</title>
          <description>Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is &gt;= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Independent reader assessed ORR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="26.0" upper_limit="47.7"/>
                    <measurement group_id="O2" value="45" lower_limit="33.6" upper_limit="55.9"/>
                    <measurement group_id="O3" value="49" lower_limit="37.3" upper_limit="60.0"/>
                    <measurement group_id="O4" value="35" lower_limit="24.3" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigator assessed ORR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="34.8" upper_limit="57.3"/>
                    <measurement group_id="O2" value="63" lower_limit="52.3" upper_limit="74.0"/>
                    <measurement group_id="O3" value="74" lower_limit="64.4" upper_limit="84.3"/>
                    <measurement group_id="O4" value="39" lower_limit="28.1" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent reader assessed ORR. As per the protocol, if the conclusions from the investigator and independent assessments of response rate were the same, the investigator assessment was considered the primary analysis of response rate. If the conclusions were different, the independent radiology reader assessment was considered the primary analysis of response rate. The conclusions were different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR. As per the protocol, if the conclusions from the investigator and independent assessments of response rate were the same, the investigator assessment was considered the primary analysis of response rate. If the conclusions were different, the independent radiology reader assessment was considered the primary analysis of response rate. The conclusions were different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall “test of treatment difference” (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by study site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed ORR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response</title>
        <description>Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately</description>
        <time_frame>Day 1 up to 95 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response</title>
          <description>Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Independent Assessed SD Disease Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="58.0" upper_limit="78.9"/>
                    <measurement group_id="O2" value="75" lower_limit="65.3" upper_limit="84.7"/>
                    <measurement group_id="O3" value="80" lower_limit="70.6" upper_limit="88.9"/>
                    <measurement group_id="O4" value="58" lower_limit="46.9" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigator Assessed Disease Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="62.3" upper_limit="82.4"/>
                    <measurement group_id="O2" value="83" lower_limit="74.4" upper_limit="91.4"/>
                    <measurement group_id="O3" value="91" lower_limit="83.9" upper_limit="97.2"/>
                    <measurement group_id="O4" value="69" lower_limit="58.4" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Independent assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed disease control rate (DCR), ie, SD &gt;= 16 weeks, or CR or PR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparison was performed only if this test was significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessed DCR</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimates for Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.</description>
        <time_frame>Day 1 up to 95 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates for Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Independent Assessment for PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="7.3" upper_limit="15.0"/>
                    <measurement group_id="O2" value="12.8" lower_limit="9.0" upper_limit="14.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="10.9" upper_limit="16.6"/>
                    <measurement group_id="O4" value="7.5" lower_limit="7.2" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigator Assessment for PFS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="8.9" upper_limit="14.6"/>
                    <measurement group_id="O2" value="7.5" lower_limit="7.2" upper_limit="9.3"/>
                    <measurement group_id="O3" value="14.6" lower_limit="10.0" upper_limit="18.9"/>
                    <measurement group_id="O4" value="7.8" lower_limit="6.3" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0498</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0524</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.607</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.495</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.568</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.972</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.702</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression</title>
        <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
        <time_frame>Day 1 - 95 weeks</time_frame>
        <population>Patients with a confirmed CR or PR were included in this analysis. Patients who did not progress or die were censored at the last known time when patient was progression free. Patients who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression</title>
          <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
          <population>Patients with a confirmed CR or PR were included in this analysis. Patients who did not progress or die were censored at the last known time when patient was progression free. Patients who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.2" upper_limit="23.9"/>
                    <measurement group_id="O2" value="13.2" lower_limit="11.3" upper_limit="14.9"/>
                    <measurement group_id="O3" value="15.1" lower_limit="10.9" upper_limit="16.7"/>
                    <measurement group_id="O4" value="9.0" lower_limit="7.5" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Independent assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression</title>
        <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
        <time_frame>Day 1 - 95 weeks</time_frame>
        <population>Patients with a confirmed CR or PR were included in this analysis. Patients who did not progress or die were censored at the last known time when patient was progression free. Patients who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression</title>
          <description>Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.</description>
          <population>Patients with a confirmed CR or PR were included in this analysis. Patients who did not progress or die were censored at the last known time when patient was progression free. Patients who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="10.3" upper_limit="19.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="7.4" upper_limit="12.4"/>
                    <measurement group_id="O3" value="14.8" lower_limit="12.8" upper_limit="19.2"/>
                    <measurement group_id="O4" value="15.1" lower_limit="11.0" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons was performed only if this test was significant.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Investigator assessment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate for Overall Survival (OS)</title>
        <description>Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).</description>
        <time_frame>Day 1 to 221 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate for Overall Survival (OS)</title>
          <description>Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="21.7" upper_limit="38.9"/>
                    <measurement group_id="O2" value="22.2" lower_limit="16.9" upper_limit="29.4"/>
                    <measurement group_id="O3" value="33.8" lower_limit="29.1" upper_limit="41.3"/>
                    <measurement group_id="O4" value="26.6" lower_limit="19.0" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>A step-down approach was used to compare treatment regimens. First an overall &quot;test of treatment difference&quot; (a 3-degree-of -freedom test) was performed. Pairwise comparisons were performed only if this test was significant.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.686</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.740</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts</title>
        <description>Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.</description>
        <time_frame>Day 1 up to 125 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug, and had blood tests performed following treatment. Three participants dropped out after a single dose so have no post-treatment lab values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts</title>
          <description>Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug, and had blood tests performed following treatment. Three participants dropped out after a single dose so have no post-treatment lab values.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.004"/>
                    <measurement group_id="O2" value="1.51" spread="0.960"/>
                    <measurement group_id="O3" value="1.11" spread="0.628"/>
                    <measurement group_id="O4" value="0.38" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="1.187"/>
                    <measurement group_id="O2" value="3.15" spread="1.228"/>
                    <measurement group_id="O3" value="2.68" spread="0.817"/>
                    <measurement group_id="O4" value="1.60" spread="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.1" spread="59.16"/>
                    <measurement group_id="O2" value="192.1" spread="57.82"/>
                    <measurement group_id="O3" value="172.6" spread="46.39"/>
                    <measurement group_id="O4" value="161.8" spread="49.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment-Emergent, Treatment-Related Adverse Events</title>
        <description>Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.</description>
        <time_frame>Day 1 up to 125 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-Emergent, Treatment-Related Adverse Events</title>
          <description>Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;= 1 adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 severe (grade 3-5) treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-5 Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-5 Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-5 Sensory neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 AE with outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related AE with outcome of death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related AE drug discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related AE drug dosage reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 treatment-related AE drug interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts</title>
        <description>Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.</description>
        <time_frame>Day 1 up to 125 weeks</time_frame>
        <population>The treated population consisted of all randomized participants who received at least one dose of study drug, and had blood tests performed following treatment. Three participants dropped out after a single dose so have no post-treatment lab values.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-007 300 mg/m^2 q3w</title>
            <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
          </group>
          <group group_id="O2">
            <title>ABI-007 100 mg/m^2 Weekly</title>
            <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O3">
            <title>ABI-007 150 mg/m^2 Weekly</title>
            <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel 100 mg/m^2 q3w</title>
            <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
          </group>
        </group_list>
        <measure>
          <title>Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts</title>
          <description>Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.</description>
          <population>The treated population consisted of all randomized participants who received at least one dose of study drug, and had blood tests performed following treatment. Three participants dropped out after a single dose so have no post-treatment lab values.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.1" spread="10.58"/>
                    <measurement group_id="O2" value="106.7" spread="10.72"/>
                    <measurement group_id="O3" value="105.6" spread="11.31"/>
                    <measurement group_id="O4" value="107.1" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to 125 weeks</time_frame>
      <desc>Treatment-emergent AEs defined as AEs that begin or worsen in grade after the first dose of study drug through 30 days after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>ABI-007 300 mg/m^2 q3w</title>
          <description>ABI-007 300 mg/m^2 administered once every third week (q3w).</description>
        </group>
        <group group_id="E2">
          <title>ABI-007 100 mg/m^2 Weekly</title>
          <description>ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
        </group>
        <group group_id="E3">
          <title>ABI-007 150 mg/m^2 Weekly</title>
          <description>ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest</description>
        </group>
        <group group_id="E4">
          <title>Docetaxel 100 mg/m^2 q3w</title>
          <description>Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel peristalsis increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation localised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma glutamyl transferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications of this multicenter trial should include input from INVESTIGATORS, his/her colleagues, and SPONSOR personnel. Such input should be reflected in publication authorship, and agreement regarding order of authors should be established before writing a manuscript. Subsequent to the multicenter publication or one year after completion of the study, whichever occurs first, an investigator and/or his/her colleagues may publish the results of INVESTIGATOR's part of the study independently.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Trials Disclosure</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>1-888-260-1599</phone>
      <email>clinicaltrialdisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

